Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • COMMENT

Accelerating progress in immune cell therapy for solid tumours

Collaborative translational research and adaptive clinical trial design are needed to accelerate the advancement of novel T cell therapies towards achieving cures in solid tumours.
By
  1. Adrian Bot

    1. Capstan Therapeutics, San Diego, CA, USA.

  2. Mark Dudley

    1. Instill Bio, Dallas, TX, USA.

  3. Daniel Shelley

    1. Poltreg, Gdańsk, Poland.

  4. Panagiota A. Sotiropoulou

    1. T-knife Therapeutics, San Francisco, CA, USA.

Evidence of objective responses across multiple CAR-T cell and other T cell therapies has established the clinical potential of immune cell therapies beyond haematological malignancies. The field should be shifting its focus towards achieving response durability, complete remission and, ultimately, cures. Achieving this goal will require coordinated efforts across sectors, supported by adaptive clinical trial designs, guided by translational research and enabled by emerging technologies. Here, we outline a path to accelerate progress, based on a cross-industry round table of cell therapy leaders, convened at the 2024 Annual CAR-TCR Summit organized by Hanson Wade in Boston.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 25, 1-2 (2026)

doi: https://doi.org/10.1038/d41573-025-00191-y

References

  1. Parums, D. V. A review of CAR T cells and adoptive T-cell therapies in lymphoid and solid organ malignancies. Med. Sci. Monit. 31, e948125 (2025).

    PubMed  Google Scholar 

  2. Uslu, U. & June, C. H. Beyond the blood: expanding CAR T cell therapy to solid tumors. Nat. Biotechnol. 43, 506–515 (2025).

    Article  PubMed  Google Scholar 

  3. Salas-Benito, D., Berger, T. R. & Maus, M. V. Stalled CARs: Mechanisms of resistance to CAR T cell therapies. Annu. Rev. Cancer Biol. 7, 23–42 (2023).

    Article  Google Scholar 

  4. Galassi, C., Chan, T. A., Vitale, I. & Galluzzi, L. The hallmarks of cancer immune evasion. Cancer Cell 42, 1825–1863 (2024).

    Article  PubMed  Google Scholar 

  5. Li, Y-R., Zhu, Y., Halladay, T. & Yang, L. In vivo CAR engineering for immunotherapy. Nat. Rev. Immunol. 25, 725–744 (2025).

    Article  PubMed  Google Scholar 

Download references

Supplementary Information

  1. Supplementary Fig. 1

Competing Interests

A.B. is an advisor to AbbVie Inc, Cartesian Therapeutics, Elicio Therapeutics and A2 Biotherapeutics, and board member of Immuthera. P.A.S is employed as Chief Scientific Officer of T-knife Therapeutics, Inc.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links